Nanoform technology delivers successful results for Herantis CDNF drug candidate
Press release Nanoform Finland Plc September 9, 2021 08:00 a.m. Finnish time / 07:00 a.m. Swedish time Nanoform technology delivers successful results for Herantis CDNF drug candidate Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced that results from the Nanoform Proof of Concept (PoC) project show that